Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

European Journal of Cancer

Volumn 47, Issue 12, 2011, Pages 1772-1778

  Amit, O ^a   Mannino, F ^a   Stone, A M ^b   Bushnell, W ^a   Denne, J ^c   Helterbrand, J ^d   Burger, H U ^e  

^a GLAXOSMITHKLINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

^d GENENTECH INC   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Discordance; Independent review; Meta analysis; Progression free survival

Indexed keywords

ARTICLE; BLINDED INDEPENDENT CENTRAL REVIEW; BREAST CANCER; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EVALUATION; HUMAN; INSTITUTIONAL REVIEW; KIDNEY CANCER; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NEOPLASM; PHARMACEUTICAL RESEARCH AND MANUFACTURERS ASSOCIATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELIABILITY; SYSTEMATIC REVIEW; THERAPY EFFECT;

ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MEDICAL AUDIT; NEOPLASMS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; UNITED STATES;

EID: 80051550048     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.013     Document Type: Article

References (33)

1. J.E. Dancey, L.E. Dodd, and R. Ford Recommendations for the assessment of progression in randomised cancer treatment trials Eur J Cancer 45 2009 281 289
2. K. Shamsi, and R.H. Patt Onsite image evaluations and independent image blinded reads: close cousins or distant relatives? J Clin Oncol 27 2009 2103 2104
3. P.A. Tang, G.R. Pond, and E.X. Chen Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials Ann Oncol 21 1 2010 19 26
4. L.E. Dodd, E.L. Korn, and B. Freidlin Blinded independent central review of progression-free-survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26 2008 3791 3796
5. A.M. Stone, W. Bushnell, and J. Denne Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group Eur J Cancer 47 12 2011 1763 1771
6. J. Pogue, S.D. Walter, and S. Yusuf Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs Clin. Trials 6 2009 239 251
7. K. Kemsley, D. Ghiorgiu, and N. Schmitt Use of progression-free survival in advanced melanoma: comparison of central and site review J Clin Oncol 27 2007 18s [Suppl.; abstr. 1011]
8. C.N. Sternberg, C. Szczylik, and E. Lee A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) J Clin Oncol 27 2009 15s [Suppl.; abstr. 5021]
9. B.J. Escudier, J. Bellmunt, and S. Negrier Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) J Clin Oncol 27 2009 15s [Suppl.; abstr. 5020]
10. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
11. B. Escudier, T. Eisen, and W. Stafler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
12. FDA: FDA Medical Review: NDA 22-334 Afinitor (everolimus), .
13. Ravaud A, Hawkins R, Gardner JP, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol doi:10.1200/JCO.2007.14.5029.
14. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care alone in patients with chemotherapy - refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
15. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol doi:10.1200/JCO.2008.19.8135.
16. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 8 2001 2282 2292 (Pubitemid 32366981)
17. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitibine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 21 2001 4097 4106 (Pubitemid 33049527)
18. M.L. Rothenberg, J.V. Cox, and C. Butts Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III non-inferiority study Ann Oncol 19 10 2008 1720 1726
19. F.F. Kabbinavar, J. Schulz, and M. McCleod Addition of bevacizumab to bolus 5-FU/leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 16 2005 3697 3705
20. K.S. Albain, S. Nag, and G. Calderillo-Ruiz Global phase III study of gemacitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival J Clin Oncol 22 14s, Suppl. 510 2004
21. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitibine compared with bevacizumab plus capecitibine in patients with previously treated metastatic breast cancer. J Clin Oncol doi:10.1200/JCO.2005. 05.098.
22. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitibine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733
23. A. Di Leo, H. Gomez, and Z. Aziz Lapatinib (L) with paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized, double-blind study of 580 patients J Clin Oncol 27 18s 2007 [Suppl.; abstr 1011]
24. K.L. Blackwell, H.J. Burstein, and A.M. Storniolo Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 7 2010 1124 1130
25. Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor- positive metastatic breast cancer. J Clin Oncol doi:10.1200/JCO2009. 23.3734.
26. FDA: FDA Briefing Document Oncology Drug Advisory Committee Meeting December 5, 2007: BLA STN 125085/91.018 Avastin (bevacizumab), .
27. H.A. Fine, V.K. Puduvalli, and M.C. Chamberlain Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): a phase III study J Clin Oncol 2008 26 [Suppl.; abstr 2005]
28. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 14 2003 2636 2644 (Pubitemid 46606305)
29. R. Dummer, C. Robert, and B. Chapman AZD6244 (ARRY - 142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multi-center, phase II study J Clin Oncol 2008 26 [Suppl.; abstr 9033]
30. FDA: FDA Briefing Document Oncology Drug Advisory Committee Meeting July 15, 2009: NDA 22-447 Yondelis (Trabectedin). .
31. C.N. Sternberg, D. Petrylak, and F. Witjes Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial J Clin Oncol 2007 25 [Suppl.; abstr 5019]
32. FDA: FDA Briefing Document Oncology Drug Advisory Committee Meeting July 15, 2009: NDA 22-447 Tarceva (Erlotinib). .
33. N.J. Robert, V. Dieras, and J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 27 15s 2009 [Suppl; abstr 1005]